Apremilast inhibits inflammatory osteoclastogenesis

Degboe Y, Sunzini F, Sood S, Bozec A, Sokolova M, Zekovic A, Mcinnes IB, Schett G, Goodyear CS (2022)


Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 61

Pages Range: 452-461

Journal Issue: 1

DOI: 10.1093/rheumatology/keab315

Abstract

Objectives. Psoriatic arthritis (PsA) is associated with bone erosion and inflammation-induced bone loss, which are mediated by osteoclasts (OC) and modulated by inflammatory cytokines. Apremilast (APR) (a selective phosphodiesterase 4 inhibitor) is efficacious in PsA and acts by inhibiting cytokine production. However, there are no direct data informing whether and how APR affects osteoclast formation in humans.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Degboe, Y., Sunzini, F., Sood, S., Bozec, A., Sokolova, M., Zekovic, A.,... Goodyear, C.S. (2022). Apremilast inhibits inflammatory osteoclastogenesis. Rheumatology, 61(1), 452-461. https://dx.doi.org/10.1093/rheumatology/keab315

MLA:

Degboe, Yannick, et al. "Apremilast inhibits inflammatory osteoclastogenesis." Rheumatology 61.1 (2022): 452-461.

BibTeX: Download